Article Text

Download PDFPDF
Primary care
Paracetamol as first line for treatment of knee and hip osteoarthritis
  1. Igho J Onakpoya
  1. Department of Primary Care, University of Oxford, Oxford, UK
  1. Correspondence to Dr Igho J Onakpoya, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK; igho.onakpoya{at}phc.ox.ac.uk

Statistics from Altmetric.com

Although several clinical guidelines recommend paracetamol as a first-line agent in the management of knee and hip osteoarthritis, the authors of a recently published Cochrane review called for a review of this recommendation.

Paracetamol is widely used as a first-line treatment for symptom relief in patients with osteoarthritis (OA). It is usually preferred to non-steroidal anti-inflammatory drugs because of its better harms profile, especially in people at risk of gastrointestinal bleeding.

In a recent Cochrane review,1 the authors compared the effectiveness of paracetamol versus placebo in the management of knee or hip OA. They searched seven scientific databases for relevant studies, including randomised controlled trials of participants with hip or knee OA irrespective of the intensity or duration of symptoms. The main outcomes were pain intensity, physical …

View Full Text

Footnotes

  • Contributors IO conceived and wrote the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests IJO holds grant funding from the NIHR School of Primary Care Research (NIHR Evidence Synthesis working group Project No: 390). He is a contributor to Meyler’s Side Effects of Drugs Annual (SEDA), where he reviews reports of adverse drug reactions attributed to antihelminthic drugs.

  • Provenance and peer review Commissioned; internally peer reviewed.

  • Patient consent for publication Not required.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.